Reportlinker Adds The Global Antivirals Market: R&D Pipelines, Market Analysis and Competitive Landscape

NEW YORK, Nov 05, 2009 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue.

The Global Antivirals Market: R&D Pipelines, Market Analysis and Competitive Landscape http://www.reportlinker.com/p0158349/The-Global-Antivirals-Market-RD-Pipelines-Market-Analysis-and-Competitive-Landscape.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire The global anti-infective market is currently valued at US$66.5 billion with antiviral agents accounting for 24% of sales (excluding vaccines which target viral infectious diseases).

According to The author; new report The Antivirals Market: R&D Pipelines, Markey Analysis and Competitive Landscape, the anti-viral market will be driven by the uptake of newer anti-retroviral agents in combination therapy and the launch of ten new products for the treatment of HIV and hepatitis which will address the need of treatment-resistant patients. This will help to stem the tide of this prevalent and often lethal killer in our society today.

Pharmaceutical companies continue to develop a new generation of antiretroviral agents to overcome the issue of drug and cross-resistance. Meanwhile new drug classes are under evaluation that increases the virologists armory against these endemic and often deadly infectious diseases.

This report examines each of the antiviral classes in turn, assessing the market potential and encompassing the major infectious diseases to which they are applicable.

The following product classes are analyzed in this report: -- antisense -- attachment, entry and fusion inhibitors -- DNA polymerase inhibitors -- integrase inhibitors -- interferons -- maturation inhibitors -- monoclonal antibodies -- neuraminidase inhibitors -- NS3 protease inhibitors -- nucleoside reverse transcriptase inhibitors -- nucleotide reverse transcriptase inhibitors -- protease inhibitors -- reverse transcriptase inhibitors -- RNA polymerase inhibitors The report assesses the overall antiviral market, key classes, the drivers and resistors influencing their prescription. The report provides an overview of key products in each category, summarizing their clinical efficacy and marketing position. The overview of the current market is given in terms of segmentation by category and by leading players, therapies and their products and analyzes market trends.

The report examines promising pipeline products and their potential impact on the prescription of current and new antiviral agents and the future antiviral market.

Key features of this report: -- Overview of the antiviral market, including main infectious agents, therapeutic drug classes and key players.

-- In-depth analysis of different classes of antiviral agents, including key antiretroviral and antiviral agents and compares drugs within each class.

-- Comprehensive facts and figures for the antiviral market, including main players and therapeutic break-downs.

-- Future trends in the antiviral marketplace, driven by drug resistance, cross-resistance and patient demographics.

-- Outlook for the antiviral market, including the emergence of novel therapies, new combination therapies and the impact of generics.

1 EXECUTIVE SUMMARY To order this report: The Global Antivirals Market: R&D Pipelines, Market Analysis and Competitive Landscape http://www.reportlinker.com/p0158349/The-Global-Antivirals-Market-RD-Pipelines-Market-Analysis-and-Competitive-Landscape.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire More market research reports here!

CONTACT:

Nicolas Bombourg

Reportlinker

Email: [e-mail]

US: [phone]

Intl: [phone] SOURCE Reportlinker URL: http://www.reportlinker.com www.prnewswire.com Copyright (C) 2009 PR Newswire. All rights reserved -0- KEYWORD: New York INDUSTRY KEYWORD: HEA

MTC

PHA

IDC

PUB

WEB

CPR SUBJECT CODE: SVY